340B Report held a webinar for its subscribers last week on Second Sight Solutions’ 340B ESP platform that administers drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies. More than 800 subscribers registered to attend—a clear sign that interest in 340B ESP is intense.
The drug company restrictions that 340B ESP manages are controversial. Federal courts are deciding whether they are legal, and it could be years before the courts rule definitively. In the meantime, many 340B entities face a hard choice: Reject the requirements and forfeit 340B revenues that sustain their missions or submit the data despite deep concerns about doing so.
340B Report held a webinar for its subscribers last week on Second Sight Solutions’ 340B ESP platform that administers drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
